Pyxis Oncology has appointed Lara Sullivan to serve as its CEO. She is also joining the Boston company’s board of directors. Sullivan succeeds David Steinberg, Pyxis’s founding CEO and a general partner at Longwood Fund. Steinberg will remain on the company’s board as an independent director. Sullivan was most recently founder and president of Pfizer (NYSE: PFE) spinout SpringWorks Therapeutics (NASDAQ: SWTX). Pyxis, a cancer drug developer, launched in July backed by a $22 million Series A round of financing.